SCHEMBL2893475

SCHEMBL2893475

N#Cc1c(NC(=O)CCC2CCCCC2)sc2c1CCN(C(=O)NCCc1ccncc1)C2

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ GRM1 Q13255 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ STAT3 P40763 2/20 0.41
▸ MAPK9 P45984 1/20 0.41
▸ MAPK10 P53779 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2895632 0.92 MEN1 (0.48) MEN1KMT2AL3MBTL1GRM1SMN1; SMN2
SCHEMBL2893432 0.91 MEN1 (0.48) MEN1KMT2AL3MBTL1GRM1LMNA
SCHEMBL3420744 0.90 MEN1 (0.49) MEN1KMT2AL3MBTL1GRM1SMN1; SMN2
SCHEMBL3418594 0.88 MEN1 (0.53) MEN1KMT2AL3MBTL1GRM1SMN1; SMN2
SCHEMBL2887735 0.87 STAT3 (0.47) MEN1KMT2AL3MBTL1GRM1STAT3
SCHEMBL2893588 0.87 MEN1 (0.59) MEN1KMT2AL3MBTL1GRM1KDM4E
SCHEMBL2887976 0.85 MEN1 (0.49) MEN1KMT2AL3MBTL1GRM1LMNA
SCHEMBL2895790 0.84 SMN1; SMN2 (0.51) MEN1KMT2AL3MBTL1SMN1; SMN2KDM4E
SCHEMBL2893613 0.83 MEN1 (0.53) MEN1KMT2AL3MBTL1GRM1RECQL
SCHEMBL3415346 0.81 MEN1 (0.50) MEN1KMT2AL3MBTL1GRM1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100285149-A1 NOVEL TETRAHYDROPYRIDOTHIOPHENES 4SC AG (DE) 2010-11-11 — — US claimed
US-20100285149-A1 NOVEL TETRAHYDROPYRIDOTHIOPHENES 4SC AG (DE) 2010-11-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100285149-A1 NOVEL TETRAHYDROPYRIDOTHIOPHENES BAX, CCAR2, BCL2 MEN1 4556/4885KMT2A 2606/4885L3MBTL1 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback